Indian Pharma Sector Expands Global Footprint With Strategic Acquisitions

The Indian pharmaceutical industry has entered a phase of aggressive international expansion as of June 2026. Major players including Alembic Pharma, Akums, Aurobindo, Zydus, and Intracin Pharma are actively entering new global markets and executing strategic acquisitions. This growth is fueled by a combination of innovation, rising domestic demand, and the global shift toward a "China+1" manufacturing strategy, which positions India as a preferred alternative for pharmaceutical supply chains.

The sector's momentum is heavily supported by government initiatives, most notably the Production Linked Incentive (PLI) Scheme. With an allocation of nearly Rs 7,000 crore, this scheme is specifically designed to boost the domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and critical intermediates. This financial backing is helping companies reduce import dependency and scale up production capabilities to meet both domestic and international healthcare requirements.

Beyond national policy, regional growth is accelerating, with states like Haryana and Telangana announcing substantial manufacturing investments in June 2026. These investments are expected to enhance the country's overall healthcare infrastructure and manufacturing capacity. As Indian firms continue to expand their global footprint, the focus remains on leveraging these incentives to maintain a competitive edge in the global market while ensuring the availability of affordable, high-quality medicines.